## GILD: Gilead Sciences, Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.21 indicates fundamental undervaluation. Quality metrics strong (ROE 41%, ROA 13%). Consistent execution (4/4 quarters beat estimates). Caution: momentum weakening (-2.5% MRS).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($115.53)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 4, Bearish: 0)

**1. Federated Hermes Inc. Sells 1,885,664 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251207T121259 | Somewhat-Bullish | Relevance: 100%
-  Federated Hermes Inc. reduced its stake in Gilead Sciences, Inc. by 38.7% in the second quarter, selling 1,885,664 shares while retaining 2,980,646 shares valued at $330.46 million. Despite this sale, analysts remain largely positive on Gilead, with a "Moderate Buy" consensus rating and an average price target of $130.65. The biopharmaceutical company recently beat quarterly EPS estimates and announced a quarterly dividend of $0.79 per share.

**2. Arrowstreet Capital Limited Partnership Grows Position in Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251207T020846 | Somewhat-Bullish | Relevance: 99%
-  Arrowstreet Capital Limited Partnership significantly increased its stake in Gilead Sciences, Inc. during Q2, purchasing 372,596 additional shares for a total holding of 426,584 shares worth about $47.3 million. This increase occurred despite recent insider selling totaling $16.6 million over the past 90 days. Gilead also reported strong quarterly earnings, beating expectations, and announced a quarterly dividend of $0.79 per share.

**3. First Trust Advisors LP Sells 1,512,069 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251206T093427 | Neutral | Relevance: 99%
-  First Trust Advisors LP significantly reduced its stake in Gilead Sciences, Inc. by selling over 1.5 million shares, leaving them with 1,214,775 shares valued at $134.68 million. Other institutional investors like Vanguard Group and Geode Capital Management increased their holdings, while insider activity revealed recent sales by company directors and CFOs. Analysts maintain a "Moderate Buy" rating for Gilead Sciences with a consensus price target of $130.65.

**4. Gilead Foundation Awards Over $3 Million to Support People Living With Metastatic Breast Cancer**
- Source: Business Wire | 20251209T133229 | Bullish | Relevance: 98%
- The Gilead Foundation has announced over $3 million in new grants to enhance education, care, and support services for individuals affected by metastatic breast cancer. This funding, distributed to 53 organizations, builds on over $21 million in support since 2021, aiming to improve access to breast cancer education and care nationwide. The grants will address critical gaps, recognizing that metastatic breast cancer has a five-year relative survival rate of 29%, underscoring the need for improved patient navigation and integrated support services.

**5. L2 Asset Management LLC Buys 28,592 Shares of Gilead Sciences, Inc. $GILD**
- Source: MarketBeat | 20251208T122914 | Somewhat-Bullish | Relevance: 98%
-  L2 Asset Management LLC significantly increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 102.4% in the second quarter, purchasing an additional 28,592 shares. The biopharmaceutical company constitutes about 1.0% of L2 Asset Management LLC's holdings, valued at $6,266,000. Other institutions like WINTON GROUP Ltd and Natixis have also adjusted their positions, while company insiders have sold shares totaling over $16.6 million in the last ninety days.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-13 | Needham | $140 | $133 | +5% |
| 2025-11-13 | Scotiabank | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-13 | Needham | main | Buy |
| 2025-11-13 | Scotiabank | init | Sector Outperform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **MIXED** |
| Buys | 2 ($10.00M) |
| Sells | 14 ($7.11M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 45.0% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (-0.3%)
- Blackrock Inc.: 9.4% (+1.2%)
- FMR, LLC: 4.9% (+0.6%)
- State Street Corpora: 4.8% (-0.2%)
- Capital World Invest: 3.6% (-2.4%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-2.5% 5d) with bearish MACD, trend may be turning.
2. Insider selling cluster: $7.1M in recent transactions.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 0.21 indicates undervaluation relative to growth. Forward P/E 13.9x stretched relative to 7% growth. Quality metrics strong (ROE 41%, ROA 13%, margin 28%). Balance sheet: $4.0B free cash flow. Analyst sentiment positive (1 raises, avg +5%). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $150.4B |
| Beta | 0.33 |
| 52W Range | $88.57 - $128.70 |
| Short Interest | 1.4% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.21 |
| Forward P/E | 13.9 |
| Current P/E | 14.8 |
| YoY Growth | 6.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from -2.1% to -4.6% (-2.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 8.6pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.07x) but short-term weakness (below SMA20). MACD histogram bearish (-0.80), momentum weakening. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -4.64% (CS: 18) | Weak |
| RSI_14 | 44.5 | Neutral |
| MACD Histogram | -0.80 | Bearish |
| vs SMA20 | 0.974x | Below |
| vs SMA50 | 1.003x | Above |
| vs SMA200 | 1.072x | Above |

### Decision

- **Verdict:** HOLD
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $121.19
- **Stop Loss:** $115.53 (4.7% risk)
- **Target:** $132.51 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 88
- **Position Value:** $10,664.72
- **Portfolio %:** 10.66%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-10 (Est: $1.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.14 | $2.47 | +15.7% |
| 2025Q2 | $1.96 | $2.01 | +2.7% |
| 2025Q1 | $1.78 | $1.81 | +1.9% |
| 2024Q4 | $1.70 | $1.90 | +11.7% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*